Business Wire

45,000 More-Fuel-Efficient Aircraft, Worth US$2.9 Trillion, Predicted to Be Delivered By 2040

16.12.2021 11:00:00 EET | Business Wire | Press release

Share

The new 2021 Cirium Fleet Forecast reveals that US$2.9 trillion is expected to be spent on approximately 45,000 new and more-fuel-efficient aircraft over the next 20 years.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211215005489/en/

Published by Ascend by Cirium, the consultancy arm of aviation analytics firm Cirium , the Cirium Fleet Forecast predicts that 20-year aircraft deliveries globally by 2040 will be 4% higher than previously predicted a year ago.

This outlines a positive outlook for the aviation industry and its recovery from the COVID-19 pandemic.

COVID-19 significantly affected air travel and so aircraft deliveries, with a 43% reduction during 2020 — 600 fewer aircraft — before the recovery in 2021, albeit still 25% below the 2019 level.

As vaccination programs have been increasing globally, air travel is reopening resulting in 300 more aircraft deliveries in 2021 — despite the issues surrounding Boeing’s 787.

Rob Morris, Global Head of Consultancy at Ascend by Cirium said: “The 2021 Cirium Fleet Forecast provides an optimistic long-term forecast for aviation which sees the industry return — although structurally differently to before — to more traditional growth paths beyond 2024. Passenger traffic is predicted to grow annually at 3.7% and so the global passenger fleet will be required to increase by almost 22,000 aircraft.”

“If this forecast is realised that would take the global passenger fleet to some 47,200 aircraft by the end of 2040. The aircraft deliveries that are predicted will not only meet the rising traffic demands but will also replace older less-fuel-efficient aircraft.”

China will receive the most deliveries

The number of aircraft deliveries will vary from airline region to region, with Asian markets expected to be the engine for growth.

China is forecast to have the highest passenger traffic growth rate at over 6% — making it the country with the largest amount of deliveries achieving a 20% share.

This is significantly ahead of all other Asia-Pacific countries, which have a combined 22% share in total.

North American airlines are forecast to have 20% share and European carriers to have 17%.

The Middle East is estimated to take a 7% share, but in value terms it will be 11% by virtue of the high number of twin-aisle aircraft deliveries.

Latin America mirrors that of the Middle East with a 7% share, followed by Russia and CIS on 4% and Africa at 3%.

Majority of deliveries will be single-aisle jets

The Fleet Forecast reveals that single-aisle jets will account for 70% of total aircraft deliveries and 55% of delivery value in the next 20 years.

The core of this US$1.6 trillion market continues to be the 150-seat size aircraft, typified by the Airbus A320neo and Boeing 737 Max 8, which will make up 50% of deliveries.

Popular 180+ seater aircraft, including the A321 neo and B737 Max 10, will take an increasing annual share, with 40% of deliveries over the two decades.

New single-aisle aircraft programs from both Airbus and Boeing are forecast to be developed in the early to mid-2030s.

The US$1.1 trillion twin-aisle aircraft market will focus on B787s and A350s, with ‘mid-sized’ 250-300 seaters taking some 65% of delivery value. The highest capacity markets will be fought over by the A350-1000 and B777-9.

Deliveries in the regional markets are forecast to be worth US$150 billion. Around a third of this figure is for turboprops, led by the 70-seat sector aircraft, with a larger 90-seat size from the 2030s. Future programs include China’s MA700 and an expected new series from Embraer.

Older fleets will be replaced with new generation aircraft

About 80% of the current passenger fleet is forecast to be retired from passenger service between 2021 and 2040.

The replacement of these older aircraft — which have higher fuel burn — with new models, is becoming more important as the industry looks to drive reductions in carbon emissions and focus on sustainability.

Overall, there will be some 19,000 retirements from the end-2020 passenger fleet, in addition to the early phasing out of several relatively young aircraft.

Ascend by Cirium’s analysis forecasts an average economic life of 22 years for single-aisle aircraft and 20 years for twin-aisle aircraft.

Freighters: New builds and conversions are rising

As cargo remains strong, freighter capacity (based on available tonne kilometers) is forecast to grow at 3.3% compared to 2019 and the supply of freighter aircraft is predicted to be around 3,500 aircraft over the next 20 years.

Of this total, 30% are expected to be newbuild freighters and 70% are conversions from passenger to freighter aircraft. Around 1,050 new aircraft are forecast worth US$121 billion.

Passenger-to-freighter conversions are being driven by the growth of e-commerce, which has been boosted by more online shopping during lockdowns.

These conversion programs are focused on newer-generation aircraft types, such as the A321, B737-800, A330 and B777-300ER.

The Cirium Fleet Forecast is an independent outlook of the global commercial passenger and freighter aircraft market, based on the largest data portfolio in aviation and years of expertise.

To download an Executive Summary of the 2021 Cirium Fleet Forecast, click here.

Ends

About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com .

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media enquiries please contact:
The Cirium media team
Rachel Humphries/June Lee
media@cirium.com

The PC Agency
Paul Charles/Michael Johnson/Callum McGoldrick
cirium@pc.agency

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye